Low risk cancer: recalibrate rather than just rename?

The controversy about renaming some low risk cancers1 is partly related to the perception of “benign” and “malignant” as biologically distinct conditions, when there is a continuum of increasing risk from benign to “good cancer” and “bad cancer.”2

The distinction between good and bad cancer is generally accepted to be arbitrary, with any risk of metastasis …